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tice was first studied in the 1980s, with investigators in a double-blind trial concluding that preoperative phenytoin administration decreased seizure rates by 50%; 20 however, the study included craniotomies for a variety of pathologies, and there was no significant difference in seizure rates between the AED-treated and untreated supratentorial tumor resection groups.
A 2015 survey of surgeons revealed that more than 63% of them administer seizure prophylaxis after tumor resection in patients without a history of seizures. 3 Eighty-five percent of the surgeons who practice prophylaxis reported that they use the antiepileptic levetiracetam. The duration of prophylaxis varied from 1 week to more than 6 weeks. This suggests that a significant minority of tumor surgeons do not endorse the perioperative use of AEDs in seizure-naïve patients. This survey also revealed that 82% of the respondents would guide their future practice in this area based on the results of a well-designed randomized controlled trial (RCT).
There is no Class I evidence to support the widespread practice of administering prophylactic AEDs in patients undergoing tumor resection. Further, pharmaceuticals are not benign. Levetiracetam can cause behavioral problems (anger, apathy, irritability, neurosis), headache, drowsiness, suicidal ideation, increased blood pressure, and gastrointestinal disturbances. Phenytoin has a larger set of side effects, such as atrial conduction depression, arrhythmias, cerebral atrophy, cerebral dysfunction, peripheral neuropathy, dermatological issues, and various immunological issues. The total direct cost of a 7-day seizure prophylaxis with intravenous levetiracetam is $8784.63 and with intravenous phenytoin $8743.78. The cost-effectiveness ratio per successful seizure prophylaxis regimen (SSPR) was shown to be $10,044.91 for intravenous levetiracetam, compared with $11,525.63 for intravenous phenytoin. 12 Given that the perioperative administration of AEDs is one of the most common practices encountered in neurological intensive care patients, we conducted a systematic review of relevant studies of perioperative seizure prophylaxis in patients undergoing tumor resection. Additionally, we provide an outline of the trial that would be necessary to provide Class I evidence. This is both a knowledge update and a blueprint for moving forward.
Methods

Literature Search and Inclusion Criteria
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P) guidelines. 18 Five databases were searched between May 10 and May 13, 2017. The databases included PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL/Academic Search Complete, Web of Science, and ScienceDirect. Searches used combinations of specific terms related to neurosurgery, brain neoplasm, anticonvulsants, and prophylaxis (details of search strategies are provided in the Appendix). Only original peer-reviewed randomized clinical trials in humans whose results were published in the English language were considered for inclusion. In addition, the references of previous systematic reviews, meta-analyses, and selected studies were evaluated for the inclusion of additional studies.
Data Extraction and Outcome Measures
One reviewer (A.K.R.) evaluated and selected articles by title, abstract, and full-text review for data abstraction. Abstracted data included first author, year, location, study design, sample size, sample characteristics, tumor type, AED type, control group, timing of intervention, duration of intervention, follow-up interval, outcome definition, seizure incidence, risk estimate, and conclusions. The risk of bias (low, high, uncertain) of included trials was assessed using the Cochrane Handbook for Systematic Reviews of Interventions 10 and the following 6 domains: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other bias. The weighted average seizure rate of untreated controls was calculated based on reported values from the included studies. Power analyses were conducted using the weighted average seizure rate to estimate the number of patients required to demonstrate noninferiority within an RCT. All power analyses were based on the FarringtonManning noninferiority test performed at the 0.05 level using a noninferiority difference of 5%.
Results
Study Selection
A total of 496 unique articles were identified through the database searches and underwent title, abstract, and full-text review (Fig. 1) . After screening by title, there were 84 articles that underwent abstract review. Sixtyeight articles were subsequently excluded, and 16 articles were considered eligible for full-text review. Following the full-text review, 13 articles were excluded. Reasons for exclusion comprised a lack of perioperative seizure outcomes, 15 ,16 a heterogeneous sample of neurosurgery patients, 9 non-English language, 19, 23 absent assessment of seizure prophylaxis for brain tumor resection, 7, 22, 28 and study design other than RCT. 13, 14, 21, 24, 25 One additional study was identified through a review of the reference lists. A total of 4 studies met inclusion criteria and were considered in this systematic review (Table 1) . Of these trials, one compared prophylactic phenobarbital or phenytoin to no intervention, 8 one compared prophylactic phenytoin to no intervention, 27 one compared prophylactic gabapentin to phenytoin use, 26 and one evaluated the addition of prophylactic phenytoin to current AED therapy.
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Assessment of Risk of Bias for the Included Studies
Details from the assessment of risk of bias for included studies are presented in Fig. 2 . Despite claims of being RCTs, only 1 study reported methodology in support of random sequence generation when allocating participants to AED and control groups. Although 2 of the studies blinded researchers for outcome assessment, none of the studies had allocation concealment or blinded participants and personnel to allocated interventions. One study had incomplete data for outcomes because the trial was terminated after interim futility analysis had demonstrated that the power would be too low to show superiority between the AED and control groups.
Seizure Outcomes
Four clinical trials assessed perioperative AED prophylaxis for preventing seizures in patients undergoing resection of brain tumors (Table 1) . 2, 8, 26, 27 All of the studies included heterogeneous samples of patients with supratentorial tumors within a variety of anatomical locations. Two trials compared AED prophylaxis to no intervention, 8, 27 while the other 2 trials compared the addition of phenytoin to current AED therapy 2 and gabapentin to treatment with phenytoin, respectively. 26 There was significant diversity across studies in the timing of the intervention, duration of intervention, follow-up interval, and outcome definition. One study did not specify the timing and duration of the intervention. 8 Two studies initiated AED therapy intraoperatively and continued treatment for 7 days, 2,27 while 1 study initiated AED therapy 7 days prior to surgery and continued treatment for 6-12 months for meningiomas or indefinitely for glial tumors. 26 The follow-up interval across studies ranged from 7 days to 12 months. Early postoperative seizures were defined by a cutoff of ≤ 7 days in 2 studies 2, 8 and ≤ 30 days in another study. 27 Additional outcomes included late seizures (> 7 days) and a history of any new seizure activity. Only 1 study had a neurologist blinded to patient treatment who evaluated and confirmed the diagnosis of seizures on clinical grounds or electroencephalography. 27 Across all of the studies, there was no significant reduction in the incidence of seizures among those in the intervention groups compared with controls.
Franceschetti et al. randomly assigned 63 patients without preoperative seizures to receive phenobarbital (n = 25), phenytoin (n = 16), or no medication (n = 22). 8 Early postoperative seizures (≤ 7 days) occurred in 4 (18%) of 22 untreated patients and 3 (7%) of the 41 patients treated with phenobarbital or phenytoin, whereas late postoperative seizures (> 7 days) occurred in 3 (21%) of 14 untreated patients and 3 (12%) of 25 patients treated with phenobarbital or phenytoin. Seizure incidence did not significantly differ between groups. De Santis et al. conducted a prospective open-label RCT to determine the potential effectiveness of phenytoin in addition to a patient's current AED therapy in preventing early postoperative seizures in those undergoing craniotomy for supratentorial brain tumor. 2 Patients randomly assigned to the phenytoin group were treated intraoperatively with a loading dose of 18 mg/kg followed by 7 days of treatment adjusted according to serum concentrations. Early postoperative seizures occurred in 13% of patients in the phenytoin group and 11% of patients in the control group. The incidence of early postoperative seizures did not differ between prophylaxis and control groups. Türe et al. evaluated the postoperative effectiveness of gabapentin on acute postoperative pain as compared with phenytoin for AED prophylaxis in patients undergoing craniotomy for supratentorial tumor resection. 26 Seizure activity was assessed at 0, 15, and 30 minutes; 1, 2, 4, 6, 12, 24, and 48 hours; and 1 month postoperatively. Only 1 patient in the phenytoin group had a seizure on postoperative Day 3.
Wu et al. pursued a prospective RCT examining the perioperative use of prophylactic AEDs (phenytoin) in patients without a history of seizures. Their study was designed to accrue 142 patients using an estimated seizure incidence of 30% in the control group and 10% in the prophylaxis group. After 6 years, the study was closed after 123 patients had been enrolled and an independent interim futility analysis had demonstrated a low likelihood that either the observation or phenytoin prophylaxis group would be superior using the full sample size. At the time, early seizures were observed in only 8% of the control group, and the true power to detect a two-thirds reduction in postsurgical 30-day seizure incidence using 123 patients was 19%. The probability that there would be insufficient evidence at the end of the trial to show superiority was 0.997, and calculations using the lower-than-expected incidence of seizures of 8% demonstrated that over 700 patients would be needed to detect the anticipated difference. Among the 123 patients who were enrolled, the incidence of overall, early (≤ 30 days), late (> 30 days), and clinically significant seizures was 24%, 10%, 14%, and 3% for the prophylaxis group and 18%, 8%, 10%, and 2% for controls, respectively. There was no significant difference in seizure incidence between the control and prophylaxis groups. 27 The weighted average seizure rate was 10.65% based on reported values from control groups. Results from power analyses estimating the sample size for a noninferiority RCT are presented in Table 2 . FU = follow-up; NS = not specified; PB = phenobarbital; PHT = phenytoin; POD = postoperative day; Sz = seizure; USA = United States of America. * Study designed to assess postoperative analgesic efficacy of gabapentin compared to phenytoin. † Trial closed early due to limited power to observe significant differences between groups. ‡ After removing patients with preoperative seizures. § Conclusions only extend to short-term PHT prophylaxis plus current AED therapy.
Discussion
Clinical Implications
We conducted a systematic review of RCTs investigating perioperative seizure prophylaxis in patients without a history of seizures who were undergoing brain tumor resection, including data from 4 studies. 2, 8, 26, 27 Our review suggests that prophylactic AED administration may not be effective in preventing seizures in the perioperative period in patients without a history of seizures. Across all of the included studies, there was no significant difference in seizure incidence in the intervention groups compared with controls. Without clear evidence of improved seizure control, neurosurgeons must reconsider the routine perioperative administration of AEDs in patients without a history of seizures who are undergoing brain tumor resection. Apparently, a sizable minority of our colleagues has already done so. 8 
Limitations of Current Evidence
Current evidence has sizable limitations. Particularly striking is the lack of any trial evaluating levetiracetam. The reviewed trials investigated gabapentin, phenytoin, and phenobarbital. Levetiracetam is, by far, the AED most commonly used by tumor neurosurgeons, and its sideeffect profile compares favorably to that for older AEDs. In addition, the reviewed studies did not consistently report tumor location and pathology, despite a strong belief among tumor surgeons about the varying degrees of epileptogenicity based on pathology. Nor was seizure timing or optimal length of prophylaxis consistently specified. These are major limitations within the existing RCTs that have investigated perioperative seizure prophylaxis for brain tumor resection.
Future Directions
There is widespread consensus that an RCT is needed to provide solid grounds for or against antiseizure prophylaxis in tumor surgery. Given the consistent lack of differences found between prophylaxis and control groups, the objective moving forward should not be to determine differences between these 2 groups (that is, superiority), but rather to show that these groups do not have different seizure profiles (that is, noninferiority). Table 2 shows the required sample size for a noninferiority study to achieve 80% power in comparing a prophylactic AED group to a control group in which the AED group has a 10% seizure rate and the control group has a seizure rate that varies from 8% to 14%. All power analyses were based on the Farrington-Manning noninferiority test performed at the 0.05 level using a noninferiority difference of 5%. 6 To estimate possible enrollment, we extracted data on all of our institution's first-time supratentorial craniotomies in adults for the period of 2014-2015. One hundred ninety-seven cases of first-time supratentorial tumor resection were performed during this period. The current literature suggests an enrollment rate slightly above 50% among eligible cancer patients approached for RCTs. 17 Therefore, it is estimated that at our center, approximately 50 patients a year could be accrued to a possible AED RCT. This is clearly too few to expect a well-powered study conducted in a timely manner; therefore, such a trial would undoubtedly require multiple centers. To estimate the number needed, a guide is given but we assumed a 4-year accrual of 50 patients per site per year. These values should only be used as a guide as they do not incorporate any intersite variation. It is possible that including sites with larger patient volumes could significantly reduce the number of sites required for such a study.
We propose that such a trial would compare levetiracetam to placebo, with accrual occurring over a 4-year period. Levetiracetam would be chosen since its use reflects current practice; it is associated with similar efficacy and fewer adverse effects compared to other anticonvulsants. Outcome measures would include seizure incidence at 7 and 30 days postoperatively. Prophylaxis would be administered at the time of surgery and continued for 7 days 
Conclusions
The question of whether to use perioperative seizure prophylaxis for patients undergoing brain tumor resection is unresolved. The use of AEDs postoperatively has become routine across major academic centers worldwide despite evidence indicating no significant reduction in the incidence of seizure among patients who receive prophylactic AEDs. Remarkably, the most commonly used AED, levetiracetam, has not been studied for this application in an RCT. There are significant limitations in the available evidence, as outlined above. To determine with any confidence and statistical significance that there is noninferiority in the seizure rate when giving or withholding AEDs, a large multicenter RCT should be performed. 
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